Animal models are established, important tools for preclinical safety and efficacy testing. Companies are advancing more “humanized” models to better reflect human responses, while at the same time ...
New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...
HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates ...
The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...
Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...
Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...
Irisin, a hormone released during exercise, appears to directly shield neurons from damage in a mouse model of multiple ...
Preclinical NHP data demonstrate significant fat‑specific weight loss with RV‑8451, while preserving lean mass and showing no gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results